Patient-derived skin tumor organoids with immune cells respond to metformin

Cell organoid (Print), Год журнала: 2024, Номер unknown

Опубликована: Май 1, 2024

Surgery is the primary treatment for skin tumors, but it can result in scarring and distress patients. Developing alternative therapeutic methods necessitates suitable in vitro models, which are currently limited accurately representing vivo cell types microenvironment of tumors. Here, we present a practical approach creating patient-derived tumor organoids that effectively replicate histological characteristics mutational profiles observed clinical tissues. Utilizing single-cell sequencing, identified up to 11 distinct within organoid samples, encompassing various system cells immune cells. Furthermore, demonstrate applicability bermatofibrosarcoma protuberans (DFSP) assessing their responses imatinib metformin. Our findings reveal metformin, contrast imatinib, modulate expression downstream genes through signaling pathways. results underscore ability DFSP preserve key features tissues, including presence multiple types, especially Importantly, our provide convenient investigating effects drugs elucidating underlying molecular mechanisms.

Язык: Английский

---

Unveiling the antitumor synergy between pazopanib and metformin on lung cancer through suppressing p-Akt/ NF-κB/ STAT3/ PD-L1 signal pathway

Biomedicine & Pharmacotherapy, Год журнала: 2024, Номер 180, С. 117468 - 117468

Опубликована: Сен. 26, 2024

Язык: Английский

---

Bibliometric analysis of metformin as an immunomodulator (2013–2024)

Frontiers in Immunology, Год журнала: 2025, Номер 15

Опубликована: Янв. 8, 2025

Metformin, the frontline treatment for diabetes, has considerable potential as an immunomodulator; however, detailed bibliometric analyses on this subject are limited. This study extracted 640 relevant articles from Web of Science (WOS) Core Collection and conducted visual using Microsoft Excel, VOSviewer, CiteSpace. The findings showed that research immunomodulatory function metformin grown steadily since 2017, with China United States being leading contributors. These studies have mostly been published in journals such International Journal Molecular Sciences, Cancers, Frontiers Immunology, Scientific Reports. Keyword co-occurrence analysis highlighted metformin's role immunomodulator, particularly context tumor immune microenvironment, immunosuppressive checkpoints, derivatives. Recent application aging, autoimmune diseases, COVID-19, tuberculosis. Additionally, its regulating inflammation gut microbiota is also investigated. Overall, effects were investigated anti-tumor, antiviral, anti-aging, disease research. highlights scope use these fields, while significantly enhancing clinical value a repurposed drug.

Язык: Английский

---

Metformin as an immunomodulatory agent in enhancing head and neck squamous cell carcinoma therapies

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Год журнала: 2025, Номер 1880(2), С. 189262 - 189262

Опубликована: Янв. 17, 2025

Язык: Английский

---

Emerging insights into the impact of systemic metabolic changes on tumor-immune interactions

Cell Reports, Год журнала: 2025, Номер 44(2), С. 115234 - 115234

Опубликована: Янв. 23, 2025

Язык: Английский

---